Multi Dimensional Precise Exploration of Immunoconsolidation Therapy for Locally Advanced NSCLC After Chemo-radiotherapy

  • End date
    Dec 31, 2022
  • participants needed
  • sponsor
    Fudan University
Updated on 15 February 2021


The purpose of this study is to carry out a prospective observational study in patients with locally advanced NSCLC receiving radical concurrent chemoradiotherapy and follow-up immune consolidation therapy. By detecting ctDNA and TILs of the patients, we explored the value of blood dynamic monitoring of ctDNA in patients with prognosis stratification and treatment effect, and explored the patients before and after concurrent chemoradiotherapy and immune consolidation therapy The characteristics of DNA, RNA, T cells and other biomarkers were correlated with the efficacy and prognosis.

Condition Non-Small Cell Lung Cancer, Chemotherapy, Chemotherapy, Chemoradiation, Chemoradiotherapy, ctDNA, nsclc
Clinical Study IdentifierNCT04741633
SponsorFudan University
Last Modified on15 February 2021


Yes No Not Sure

Inclusion Criteria

Non small cell lung cancer patients confirmed by pathology
They were 18-80 years old
The tumor could not be resected or could not tolerate surgery
Planed to receive chemoradiotherapy and subsequent immunoconsolidation therapy
Clinical stage III (AJCC, 8th Edition, 2017)
After systematic detection of non-small cell lung cancer core indicators including EGFR, ALK, ros1, KRAS, ntrk, TMB, etc
Patient informed consent

Exclusion Criteria

After radiotherapy and chemotherapy, the disease progressed and immune maintenance therapy could not be carried out
It can not cooperate with the completion of baseline mutation screening and subsequent sample detection
Factors judged by other researchers not suitable for further study
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note